FGF-23 and vitamin D: don't shoot the messenger? | Zendy

Robert Fish | Zendy; John Cunningham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

FGF-23 and vitamin D: don't shoot the messenger?

Author(s) -

Robert Fish,

John Cunningham

Publication year - 2012

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs088

Subject(s) - fibroblast growth factor 23 , medicine , vitamin d and neurology , parathyroid hormone , kidney disease , endocrinology , secondary hyperparathyroidism , fibroblast growth factor , hyperparathyroidism , adverse effect , vitamin , regulator , calcium , biochemistry , receptor , biology , gene

The discovery of fibroblast growth factor-23 (FGF-23) as a key regulator of phosphate and vitamin D metabolism has forced a rethink about the mineral and bone disorder of chronic kidney disease (CKD). FGF-23 powerfully predicts adverse cardiovascular outcomes in patients with CKD and an important question is whether treatment regimens should now be tailored to address FGF-23 levels in addition to those of calcium, phosphate, parathyroid hormone and vitamin D. Nevertheless, despite the known action of active vitamin D therapies to increase FGF-23, this should probably still form an important part of the management of patients with hyperparathyroidism and perhaps at low doses of essentially all patients with advanced renal disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research